DURECT (NASDAQ:DRRX) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of DURECT (NASDAQ:DRRX) in a research note published on Sunday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of DURECT in a research note on Thursday, March 27th.

DURECT Stock Performance

NASDAQ DRRX opened at $0.75 on Friday. The firm’s fifty day moving average price is $0.78 and its two-hundred day moving average price is $0.93. The stock has a market cap of $23.15 million, a PE ratio of -1.22 and a beta of 0.88. DURECT has a fifty-two week low of $0.70 and a fifty-two week high of $1.88.

DURECT (NASDAQ:DRRX) last issued its quarterly earnings data on Wednesday, March 26th. The specialty pharmaceutical company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.12). The firm had revenue of $2.30 million for the quarter, compared to the consensus estimate of $6.91 million. DURECT had a negative return on equity of 300.62% and a negative net margin of 198.58%. As a group, sell-side analysts predict that DURECT will post -0.5 earnings per share for the current fiscal year.

Institutional Trading of DURECT

Several institutional investors have recently modified their holdings of the business. Jane Street Group LLC raised its position in DURECT by 266.0% during the 4th quarter. Jane Street Group LLC now owns 39,196 shares of the specialty pharmaceutical company’s stock worth $29,000 after purchasing an additional 28,486 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of DURECT by 4.8% in the 3rd quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock worth $429,000 after purchasing an additional 14,658 shares during the period. Finally, Richmond Brothers Inc. boosted its stake in shares of DURECT by 12.2% in the 4th quarter. Richmond Brothers Inc. now owns 1,281,176 shares of the specialty pharmaceutical company’s stock valued at $961,000 after purchasing an additional 138,920 shares during the last quarter. Institutional investors own 28.03% of the company’s stock.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.